AEGEAN

Evaluate the effect of RAS blockers discontinuation versus continuation on clinical course of patients infected with COVID-19.

A phase IV, multicentric, randomized, real-world pragmatic study that compares a strategy of early LDL reduction with anti-PCSK9 in patients defined as extreme high risk by 2019 ESC/EAS guidelines vs....

To assess if flecainide is more efficient than standard of care (control group) to prevent AF occurrence during the 3 months after PFO closure.